Skip to main content

A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment.

Open
  • Protocol code: CLIN-60000-461
  • EudraCT code: No aplica
  • Research group: Childhood Cancer and Blood Disorders
  • Service: Pediatric Oncohematology
  • Principal investigator:  Gros Subias, Luís
  • Pathology: Tumors
  • Phase: Fase II